

# Correction of Psoriatic T Cell Signatures by Deucravacitinib

NCT05858645

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	University of California, San Francisco
<b>Enrollment</b>	25 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- years of age or older
- Patients with moderate-severe psoriasis (BSA  $\geq$  10%, PASI  $\geq$  12, static Physician's Global Assessment (sPGA) 3 and above)

### Exclusion (7)

- taking systemic immunosuppressives in the last 12 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.

... and 2 more (see full listing online)

## Locations (1 total)

---

University of California, San Francisco, San Francisco, California, United States